このページの翻訳は実験的なもので、現在開発中です。お待ちしております

MDxHealth 将来の成長

Future 基準チェック /16

MDxHealthは、59.8%と15.5%でそれぞれ年率59.8%で利益と収益が成長すると予測される一方、EPSはgrowで66.7%年率。

主要情報

59.8%

収益成長率

66.7%

EPS成長率

Biotechs 収益成長	35.6%
収益成長率	15.5%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	18 Dec 2023

今後の成長に関する最新情報

Recent updates

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

Oct 05

業績と収益の成長予測

ENXTBR:MDXH - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	96	-13	-3	1	4
12/31/2024	82	-26	-20	-15	5
12/31/2023	70	-43	-26	-20	5
9/30/2023	64	-45	-30	-24	N/A
6/30/2023	55	-48	-35	-29	N/A
3/31/2023	46	-47	-34	-30	N/A
12/31/2022	37	-44	-38	-34	N/A
9/30/2022	30	-40	-32	-30	N/A
6/30/2022	25	-34	-28	-26	N/A
3/31/2022	23	-31	N/A	N/A	N/A
12/31/2021	22	-29	-23	-23	N/A
9/30/2021	21	-28	-22	-21	N/A
6/30/2021	19	-28	-21	-21	N/A
3/31/2021	19	-28	N/A	N/A	N/A
12/31/2020	18	-29	-21	-20	N/A
9/30/2020	15	-36	-20	-20	N/A
6/30/2020	11	-43	-20	-20	N/A
3/31/2020	11	-43	-21	-21	N/A
12/31/2019	12	-43	-22	-22	N/A
9/30/2019	17	-37	-25	-25	N/A
6/30/2019	22	-31	-28	-27	N/A
3/31/2019	25	-32	-29	-28	N/A
12/31/2018	28	-32	-30	-29	N/A
9/30/2018	31	-30	-30	-28	N/A
6/30/2018	33	-28	-31	-27	N/A
3/31/2018	37	-20	-23	-19	N/A
12/31/2017	41	-12	-15	-10	N/A
9/30/2017	41	-9	-13	-8	N/A
6/30/2017	41	-5	N/A	-5	N/A
3/31/2017	36	-9	N/A	-11	N/A
12/31/2016	30	-13	N/A	-17	N/A
9/30/2016	26	-15	N/A	-17	N/A
6/30/2016	23	-17	N/A	-16	N/A
3/31/2016	20	-16	N/A	-15	N/A
12/31/2015	18	-14	N/A	-14	N/A
9/30/2015	16	-14	N/A	-15	N/A
6/30/2015	15	-13	N/A	-15	N/A
3/31/2015	13	-14	N/A	-17	N/A
12/31/2014	12	-15	N/A	-19	N/A
9/30/2014	10	-16	N/A	-19	N/A
6/30/2014	8	-16	N/A	-19	N/A
3/31/2014	8	-16	N/A	-17	N/A
12/31/2013	8	-16	N/A	-14	N/A
9/30/2013	7	-15	N/A	-13	N/A
6/30/2013	7	-14	N/A	-12	N/A
3/31/2013	7	-13	N/A	-11	N/A
12/31/2012	6	-12	N/A	-11	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MDXH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MDXH今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: MDXH今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: MDXHの収益 ( 15.5% ) Belgian市場 ( 6.3% ) よりも速いペースで成長すると予測されています。

高い収益成長: MDXHの収益 ( 15.5% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MDXHの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

MDxHealth 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Recent updates

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $40 million.

Mdxhealth SA Raises Earnings Guidance for the Year 2024

MDxHealth SA Revises Earnings Guidance for the Year 2024

MDxHealth SA has filed a Follow-on Equity Offering in the amount of $50 million.

Mdxhealth Adds Hereditary Prostate Cancer Genetic Test to Prostate Cancer Offering

MDxHealth SA Maintains Earnings Guidance for the Year 2024

MDxHealth SA Announces Jan Pensaert Steps Down from its Board of Directors

MDxHealth SA Provides Earnings Guidance for the Fourth Quarter and Full Year 2023 and Year 2024

MDxHealth SA to Report Q1, 2024 Results on May 08, 2024

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

MDxHealth SA Shares No Longer Be Listed and Traded on Euronext Brussels, Effective as of Close of Trading on Euronext Brussels on December 15, 2023

New minor risk - Profitability

MDxHealth SA Provides Earnings Guidance for the Year 2023

MDxHealth SA Revises Earnings Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Why Investors Shouldn't Be Surprised By MDxHealth SA's (EBR:MDXH) 29% Share Price Plunge

MDxHealth SA to Report Q3, 2023 Results on Oct 09, 2023

Consensus EPS estimates fall by 10%, revenue upgraded

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

New major risk - Share price stability

MDxHealth SA Reaffirms Revenue Guidance for the Year 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

MDxHealth (EBR:MDXH) Is Carrying A Fair Bit Of Debt

Full year 2022 earnings released: US$0.28 loss per share (vs US$0.24 loss in FY 2021)

Third quarter 2022 earnings released: US$0.078 loss per share (vs US$0.06 loss in 3Q 2021)

MDxHealth SA to Report First Half, 2023 Results on Aug 23, 2023

MDxHealth SA Provides Revenue Guidance for the Fiscal Year 2023

MDxHealth SA Revises Revenue Guidance for the Fiscal Year 2022

Price target increased to €1.20

MDxHealth SA Reaffirms Revenue Guidance for the Year 2022

Third quarter 2022 earnings released: US$0.05 loss per share (vs US$0.059 loss in 3Q 2021)

Second quarter 2022 earnings released: US$0.072 loss per share (vs US$0.06 loss in 2Q 2021)

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

MDxHealth SA (ENXTBR:MDXH) acquired Oncotype DX GPS Prostate Cancer Business from Exact Sciences Corporation (NasdaqCM:EXAS) for $100 million.

Mdxhealth Sa Announces Resignation of Rudi Mariën as Non-Executive Director

Palmetto GBA’s MolDX Issues Foundational LCD Covering the Indication for SelectMDx for Prostate Cancer

Is MDxHealth (EBR:MDXH) Using Debt In A Risky Way?

Full year 2021 earnings released

Price target increased to €1.20

MDxHealth SA Provides Revenue Guidance for the Full Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Here's Why MDxHealth (EBR:MDXH) Can Manage Its Debt Despite Losing Money

First half 2021 earnings released: US$0.12 loss per share (vs US$0.18 loss in 1H 2020)

MDxHealth (EBR:MDXH) Has Debt But No Earnings; Should You Worry?

Full year 2020 earnings released: US$0.34 loss per share (vs US$0.69 loss in FY 2019)

Revenue misses expectations

MDxHealth SA to Report Fiscal Year 2020 Results on Apr 28, 2021

MDxHealth SA to Report Fiscal Year 2020 Results on Mar 03, 2021

MDxHealth SA to Report First Half, 2021 Results on Aug 26, 2021

New 90-day high: €1.07

MDxHealth's (EBR:MDXH) Stock Price Has Reduced 75% In The Past Five Years

New 90-day high: €1.00

Is MDxHealth (EBR:MDXH) Weighed On By Its Debt Load?

Price target raised to €1.00

MDxHealth SA Suspends 2020 Guidance

New 90-day low - €0.69

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘